GLP-1 Generics Experience Rapid Growth Amid Warnings of Potential Safety Risks

GLP-1 Weight-Loss Therapies Enter Indian Market, Raising Regulatory Concerns

Key Figures:

• March 10: Date of Central Drugs Standard Control Organization (CDSCO) advisory on GLP-1 drug promotion
• March 19: Date when dozens of affordable generic weight-loss therapies are set to enter the Indian market

Market Overview

Read also: FirstClub Secures $55 Million in Funding from Peak XV, Sofina, and Other Investors 9 Months After $22 Million Series A Round

Dozens of affordable generic weight-loss therapies are poised to enter the Indian market, prompting concerns from health activists and clinicians. Multinational drugmakers and domestic companies are promoting GLP-1 (Glucagon-like peptide-1) drugs as lifestyle enhancers rather than prescription therapies with real risks.

Regulatory Action

The CDSCO issued an advisory on March 10, warning manufacturers against direct or indirect promotional activities, including the use of influencers, disease-awareness campaigns, digital outreach, and messaging that exaggerates benefits or suggests guaranteed weight-loss outcomes. The regulator stated that such strategies amount to surrogate advertising of prescription-only medicines, violating the Drugs and Cosmetics Act.

Compliance Requirements

Read also: RBI Policy Preview: A Cautionary Wait Ahead

GLP-1 drugs must not be projected as substitutes for diet, exercise, or long-term lifestyle management. Companies have been directed to submit comprehensive risk-management plans for continued market oversight.

Industry Response and Criticism

Health activists have criticized the CDSCO's advisory as too little, too late. Jitendra Chouksey, founder of fitness platform FITTR, has been petitioning regulators and courts for nearly two years. He argues that the advisory was issued only after judicial pressure and stopped short of meaningful enforcement.

Public Health Concerns

Doctors are calling for restraint as GLP-1 prescriptions surge. Dr. Shashank Joshi, a leading endocrinologist, warns that the growing culture of unsupervised use, fueled by social-media testimonials, could trigger preventable harm. He emphasizes that GLP-1 drugs are complex, once-weekly injections requiring strict nutritional adherence and expert oversight to prevent serious medical complications.